NCT06206096招募中2 期
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for Patients With RAS-mutant, Microsatellite Stable, Metastatic Colorectal Cancer: a Prospective, Open-label, Single-arm, Phase II Trial
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年5月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed non resectable, locally advanced or metastatic colorectal cancer;
- •No previous anti-tumor treatment for metastatic diseases;
- •KRAS/NRAS mutation;
- •Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
- •Life expectancy ≥ 3 months;
- •Adequate organ and bone marrow functions:
- •Absolute neutrophil count≥1.5x10^9/L; Platelet count≥100x10^9/L; Hemoglobin≥9g/dL; Serum bilirubin<1.5x the upper limit of normal(ULN); Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)<1.5x ULN; Serum creatinine<1.5x ULN; Endogenous creatinine clearance rate ≥ 50ml / min;
- •Women of childbearing age need to take effective contraceptive measures.
排除标准
- •Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors or previous use of immune checkpoint inhibitors;
- •With BRAF mutation or MSI-H status;
- •Other untreated or concurrent tumors (except cervical carcinoma in situ, treated basal cell carcinoma or superficial bladder tumor, or if the tumor is cured and there is no evidence of disease for more than 3 years);
- •Have received other systemic anti-tumor treatments, including chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy within 4 weeks before enrollment;
- •There was central nervous system (CNS) metastasis or previous brain metastasis before enrollment;
- •Have received any surgery or invasive treatment or operation within 4 weeks before enrollment;
- •Have received Local anti-tumor therapy such as hepatic artery interventional embolization, liver metastasis cryoablation or radiofrequency ablation within 4 weeks before enrollment;
- •Uncontrolled malignant ascites;
- •Participated in other clinical trials within 4 weeks before enrollment, and received corresponding experimental drug treatment;
- •Allergic to the study drug or any of its adjuvants;
- •International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 × ULN；
- •The researchers judged clinically significant electrolyte abnormalities;
- •Hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg; Patients currently have poorly controlled diabetes (fasting glucose level is greater than CTCAE grade 2 after regular treatment);
- •Patients with dysphagia, active peptic ulcer, intestinal obstruction, active gastrointestinal bleeding, peptic perforation, malabsorption syndrome or uncontrolled intestinal inflammatory diseases;
- •Any disease or state affecting drug absorption before enrollment, or the patient cannot take oral medication;
- •Patients with obvious evidence of bleeding tendency or medical history within 3 months before enrollment, hemoptysis or thromboembolism within 12 months;
- •Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure, New York Heart Association (NYHA) grade > 2; ventricular arrhythmia requiring drug treatment; LVEF (left ventricular ejection fraction) < 50%;
- •Active infection or serious infection that is not controlled by drug (≥CTCAE v5.0 Grade 2）;
- •History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10^4/ml or >2000 IU/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10^3/m); hepatitis and cirrhosis;
- •Women who are pregnant or lactating;
- •Urinary protein ≥ ++, and the 24-hour urine protein quantification is greater than 1.0g;
- •Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.
研究组 & 干预措施
CAPOX+BEV+PD-1
Experimental
干预措施: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody (Drug)
结局指标
主要结局
ORR
时间窗: up to 3 years
The proportion of patients with a confirmed complete response or partial response
次要结局
- PFS(up to 3 years)
- OS(up to 3 years)
- DCR(up to 3 years)
- Safety and tolerability by incidence, severity and outcome of adverse events(up to 3 years)
研究者
Dai, Guanghai
Professor
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver MetastasesColorectal CancerNCT06124729The First Affiliated Hospital with Nanjing Medical University50
进行中（未招募）
2 期
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II StudyMetastatic Nasopharyngeal CarcinomaChemotherapy EffectNCT04872582XIANG YANQUN33
Unknown
1 期
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial CancerEndometrial CancerNCT04157491Sun Yat-sen University23
招募中
2 期
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell LymphomaImmune Checkpoint InhibitorChemotherapy EffectEpigenetic DisorderNK/T-cell Lymphoma of Nasal CavityNCT04414969Hunan Cancer Hospital35
招募中
不适用
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular CarcinomaHepatocellular CarcinomaNCT05701553Shanghai Zhongshan Hospital20